Cargando…
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300176/ https://www.ncbi.nlm.nih.gov/pubmed/28182722 http://dx.doi.org/10.1371/journal.pone.0171753 |
_version_ | 1782506140164161536 |
---|---|
author | Chen, Yu-Wei Wang, Jun-Sing Sheu, Wayne H-H Lin, Shih-Yi Lee, I-Te Song, Yuh-Min Fu, Chia-Po Lee, Chia-Lin |
author_facet | Chen, Yu-Wei Wang, Jun-Sing Sheu, Wayne H-H Lin, Shih-Yi Lee, I-Te Song, Yuh-Min Fu, Chia-Po Lee, Chia-Lin |
author_sort | Chen, Yu-Wei |
collection | PubMed |
description | INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269). RESULTS: There were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. CONCLUSIONS: The HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors. |
format | Online Article Text |
id | pubmed-5300176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-53001762017-02-28 Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes Chen, Yu-Wei Wang, Jun-Sing Sheu, Wayne H-H Lin, Shih-Yi Lee, I-Te Song, Yuh-Min Fu, Chia-Po Lee, Chia-Lin PLoS One Research Article INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level. The subjects were divided into two groups based on HGI (HGI = observed HbA1c - estimated HbA1c). Mixed model repeated measures were used to compare the treatment efficacy after 1 year in patients with a low (HGI<0, n = 199) and high HGI (HGI≧0, n = 269). RESULTS: There were no significant group differences in mean changes of FPG after 1 year (-12.8 and -13.4 mg/dL in the low and high HGI groups, respectively). However, the patients with a high HGI had a significantly greater reduction in HbA1c from baseline compared to those with a low HGI (-1.9 versus -0.3% [-20.8 versus -3.3 mmol/mol]). Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. CONCLUSIONS: The HGI index derived from FPG and HbA1c may be able to identify who will have a better response to DPP-4 inhibitors. Public Library of Science 2017-02-09 /pmc/articles/PMC5300176/ /pubmed/28182722 http://dx.doi.org/10.1371/journal.pone.0171753 Text en © 2017 Chen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Chen, Yu-Wei Wang, Jun-Sing Sheu, Wayne H-H Lin, Shih-Yi Lee, I-Te Song, Yuh-Min Fu, Chia-Po Lee, Chia-Lin Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title_full | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title_fullStr | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title_full_unstemmed | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title_short | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
title_sort | hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300176/ https://www.ncbi.nlm.nih.gov/pubmed/28182722 http://dx.doi.org/10.1371/journal.pone.0171753 |
work_keys_str_mv | AT chenyuwei hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT wangjunsing hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT sheuwaynehh hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT linshihyi hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT leeite hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT songyuhmin hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT fuchiapo hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes AT leechialin hemoglobinglycationindexasausefulpredictoroftherapeuticresponsestodipeptidylpeptidase4inhibitorsinpatientswithtype2diabetes |